A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells
出版年份 2015 全文链接
标题
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells
作者
关键词
-
出版物
mAbs
Volume 7, Issue 3, Pages 584-604
出版商
Informa UK Limited
发表日期
2015-05-21
DOI
10.1080/19420862.2015.1029216
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Update on obinutuzumab in the treatment of B-cell malignancies
- (2014) Tim Illidge et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas
- (2014) Marcus Remer et al. Immunotherapy
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
- (2013) Raymund Buhmann et al. Journal of Translational Medicine
- IgBLAST: an immunoglobulin variable domain sequence analysis tool
- (2013) Jian Ye et al. NUCLEIC ACIDS RESEARCH
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Blinatumomab: A historical perspective
- (2012) Dirk Nagorsen et al. PHARMACOLOGY & THERAPEUTICS
- Capture, crawl, cross: the T cell code to breach the blood–brain barriers
- (2012) Britta Engelhardt et al. TRENDS IN IMMUNOLOGY
- The future of anti-CD20 monoclonal antibodies: are we making progress?
- (2011) W. Alduaij et al. BLOOD
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
- (2011) Dirk Nagorsen et al. EXPERIMENTAL CELL RESEARCH
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Does VEGF secreted by leukemic cells increase the permeability of blood–brain barrier by disrupting tight-junction proteins in central nervous system leukemia?
- (2011) Sara Feng et al. MEDICAL HYPOTHESES
- Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
- (2010) Claudia Bluemel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started